Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells.

Ding ZC, Habtetsion T, Cao Y, Li T, Liu C, Kuczma M, Chen T, Hao Z, Bryan L, Munn DH, Zhou G.

Sci Rep. 2017 Sep 22;7(1):12168. doi: 10.1038/s41598-017-12488-z.

2.

The chromatin accessibility signature of human immune aging stems from CD8+ T cells.

Ucar D, Márquez EJ, Chung CH, Marches R, Rossi RJ, Uyar A, Wu TC, George J, Stitzel ML, Palucka AK, Kuchel GA, Banchereau J.

J Exp Med. 2017 Oct 2;214(10):3123-3144. doi: 10.1084/jem.20170416. Epub 2017 Sep 13.

PMID:
28904110
3.

Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.

Zhenjiang L, Rao M, Luo X, Sandberg E, Bartek J Jr, Schoutrop E, von Landenberg A, Meng Q, Valentini D, Poiret T, Sinclair G, Peredo IH, Dodoo E, Maeurer M.

EBioMedicine. 2017 Sep;23:20-24. doi: 10.1016/j.ebiom.2017.08.024. Epub 2017 Aug 30.

4.

Interleukin-7 and Immunosenescence.

Nguyen V, Mendelsohn A, Larrick JW.

J Immunol Res. 2017;2017:4807853. doi: 10.1155/2017/4807853. Epub 2017 Apr 6. Review.

5.

Dying to protect: cell death and the control of T-cell homeostasis.

Li KP, Shanmuganad S, Carroll K, Katz JD, Jordan MB, Hildeman DA.

Immunol Rev. 2017 May;277(1):21-43. doi: 10.1111/imr.12538. Review.

PMID:
28462527
6.

Development of CAR T cells designed to improve antitumor efficacy and safety.

Jaspers JE, Brentjens RJ.

Pharmacol Ther. 2017 Oct;178:83-91. doi: 10.1016/j.pharmthera.2017.03.012. Epub 2017 Mar 22. Review.

7.

IL-7-Induced Proliferation of Human Naive CD4 T-Cells Relies on Continued Thymic Activity.

Silva SL, Albuquerque AS, Matoso P, Charmeteau-de-Muylder B, Cheynier R, Ligeiro D, Abecasis M, Anjos R, Barata JT, Victorino RM, Sousa AE.

Front Immunol. 2017 Jan 19;8:20. doi: 10.3389/fimmu.2017.00020. eCollection 2017.

8.

Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.

Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I.

Oncoimmunology. 2016 Oct 24;5(12):e1248015. doi: 10.1080/2162402X.2016.1248015. eCollection 2016.

9.

Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon.

Krzystek-Korpacka M, Zawadzki M, Neubauer K, Bednarz-Misa I, Górska S, Wiśniewski J, Witkiewicz W, Gamian A.

Cancer Immunol Immunother. 2017 Feb;66(2):171-179. doi: 10.1007/s00262-016-1933-3. Epub 2016 Nov 19.

10.

Establishment and Maintenance of the Human Naïve CD4+ T-Cell Compartment.

Silva SL, Sousa AE.

Front Pediatr. 2016 Oct 31;4:119. eCollection 2016. Review.

11.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium.

PLoS One. 2016 Nov 2;11(11):e0162752. doi: 10.1371/journal.pone.0162752. eCollection 2016.

12.

Chemotherapy and immunotherapy: A close interplay to fight cancer?

Hanoteau A, Moser M.

Oncoimmunology. 2016 Jun 21;5(7):e1190061. doi: 10.1080/2162402X.2016.1190061. eCollection 2016 Jul. Review.

13.

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.

Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P.

Nat Commun. 2016 Aug 8;7:12335. doi: 10.1038/ncomms12335.

14.

IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.

Ding ZC, Liu C, Cao Y, Habtetsion T, Kuczma M, Pi W, Kong H, Cacan E, Greer SF, Cui Y, Blazar BR, Munn DH, Zhou G.

Oncoimmunology. 2016 Apr 25;5(6):e1171445. doi: 10.1080/2162402X.2016.1171445. eCollection 2016 Jun.

15.

Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Patil NK, Bohannon JK, Sherwood ER.

Pharmacol Res. 2016 Sep;111:688-702. doi: 10.1016/j.phrs.2016.07.019. Epub 2016 Jul 25. Review.

16.

DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.

Nie J, Zhang Y, Li X, Chen M, Liu C, Han W.

Oncotarget. 2016 Jun 21;7(25):37882-37892. doi: 10.18632/oncotarget.9352.

17.

Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.

Gill S.

Curr Hematol Malig Rep. 2016 Aug;11(4):318-25. doi: 10.1007/s11899-016-0330-5. Review.

18.

The Basis of Oncoimmunology.

Palucka AK, Coussens LM.

Cell. 2016 Mar 10;164(6):1233-1247. doi: 10.1016/j.cell.2016.01.049. Review.

19.

Human naïve regulatory T-cells feature high steady-state turnover and are maintained by IL-7.

Silva SL, Albuquerque AS, Serra-Caetano A, Foxall RB, Pires AR, Matoso P, Fernandes SM, Ferreira J, Cheynier R, Victorino RM, Caramalho I, Barata JT, Sousa AE.

Oncotarget. 2016 Mar 15;7(11):12163-75. doi: 10.18632/oncotarget.7512.

20.

Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia.

Sheikh V, Porter BO, DerSimonian R, Kovacs SB, Thompson WL, Perez-Diez A, Freeman AF, Roby G, Mican J, Pau A, Rupert A, Adelsberger J, Higgins J, Bourgeois JS Jr, Jensen SM, Morcock DR, Burbelo PD, Osnos L, Maric I, Natarajan V, Croughs T, Yao MD, Estes JD, Sereti I.

Blood. 2016 Feb 25;127(8):977-88. doi: 10.1182/blood-2015-05-645077. Epub 2015 Dec 16.

Supplemental Content

Support Center